A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance)

Relapse remains the major cause of death in older patients transplanted for Acute Myeloid Leukemia (AML) in first complete remission (CR1) or for patients with advanced Myelodysplastic Syndrome (MDS) at any age. Conventional myeloablative conditioning followed by allogeneic blood or marrow transplan...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Biol Blood Marrow Transplant
Главные авторы: Vij, Ravi, Le-Rademacher, Jennifer, Laumann, Kristina, Hars, Vera, Owzar, Kouros, Shore, Tsiporah, Vasu, Sumithira, Cashen, Amanda, Isola, Luis, Shea, Thomas, DeMagalhaes-Silverman, Margarida, Hurd, David, Meehan, Kenneth, Beardell, Frank, Devine, Steven
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790289/
https://ncbi.nlm.nih.gov/pubmed/31212080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.007
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы